{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Prednisone+acetate+1%25",
    "query": {
      "intervention": "Prednisone acetate 1%"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 140,
    "total_pages": 14,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Prednisone+acetate+1%25&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-22T20:56:59.834Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04493853",
      "title": "Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hormone-Sensitive Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Capivasertib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Abiraterone Acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "MALE",
        "summary": "18 Years to 130 Years · Male only"
      },
      "enrollment_count": 1012,
      "start_date": "2020-07-13",
      "completion_date": "2027-03-31",
      "has_results": true,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-09-22T20:56:59.834Z",
      "location_count": 33,
      "location_summary": "Tucson, Arizona • La Jolla, California • Orange, California + 29 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04493853"
    },
    {
      "nct_id": "NCT02159690",
      "title": "A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer",
        "Localized Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone acetate",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Dutasteride",
          "type": "DRUG"
        },
        {
          "name": "Degarelix",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kenneth Pienta, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 0,
      "start_date": "2014-09",
      "completion_date": "2015-01",
      "has_results": false,
      "last_update_posted_date": "2015-01-26",
      "last_synced_at": "2026-09-22T20:56:59.834Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02159690"
    },
    {
      "nct_id": "NCT00002524",
      "title": "Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Bleomycin Sulfate",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride (DOX)",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin calcium",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Pentamidine",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Trimethoprim-Sulfamethoxazole",
          "type": "DRUG"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        },
        {
          "name": "Zidovudine (AZT)",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "1993-06",
      "completion_date": "2005-10",
      "has_results": false,
      "last_update_posted_date": "2012-07-30",
      "last_synced_at": "2026-09-22T20:56:59.834Z",
      "location_count": 2,
      "location_summary": "Orlando, Florida • Houston, Texas",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002524"
    },
    {
      "nct_id": "NCT02807805",
      "title": "Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Prostate Carcinoma",
        "Recurrent Prostate Carcinoma",
        "Stage IV Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Abiraterone Acetate",
          "type": "DRUG"
        },
        {
          "name": "Niclosamide",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mamta Parikh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "19 Years and older · Male only"
      },
      "enrollment_count": 37,
      "start_date": "2016-10",
      "completion_date": "2025-12",
      "has_results": false,
      "last_update_posted_date": "2024-12-18",
      "last_synced_at": "2026-09-22T20:56:59.834Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02807805"
    },
    {
      "nct_id": "NCT03007732",
      "title": "Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "SD-101",
          "type": "DRUG"
        },
        {
          "name": "Leuprolide acetate",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone Acetate",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Stereotactic Body Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "David Oh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2017-05-17",
      "completion_date": "2025-03-31",
      "has_results": true,
      "last_update_posted_date": "2025-12-05",
      "last_synced_at": "2026-09-22T20:56:59.834Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03007732"
    },
    {
      "nct_id": "NCT02379390",
      "title": "Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer Metastatic"
      ],
      "interventions": [
        {
          "name": "Cabazitaxel XRP6258",
          "type": "DRUG"
        },
        {
          "name": "Ezalutamide",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone acetate",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 8,
      "start_date": "2015-06-17",
      "completion_date": "2018-05-10",
      "has_results": true,
      "last_update_posted_date": "2019-06-21",
      "last_synced_at": "2026-09-22T20:56:59.834Z",
      "location_count": 14,
      "location_summary": "Muscle Shoals, Alabama • Anchorage, Alaska • Anaheim, California + 11 more",
      "locations": [
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02379390"
    },
    {
      "nct_id": "NCT06060587",
      "title": "Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "ADT",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 0,
      "start_date": "2023-10-19",
      "completion_date": "2030-12-22",
      "has_results": false,
      "last_update_posted_date": "2025-10-22",
      "last_synced_at": "2026-09-22T20:56:59.834Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06060587"
    },
    {
      "nct_id": "NCT04262154",
      "title": "Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "GnRH analog",
          "type": "DRUG"
        },
        {
          "name": "Stereotactic Body Radiotherapy (SBRT)",
          "type": "RADIATION"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Follow up",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 28,
      "start_date": "2020-03-03",
      "completion_date": "2026-09",
      "has_results": true,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-09-22T20:56:59.834Z",
      "location_count": 8,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04262154"
    },
    {
      "nct_id": "NCT04421222",
      "title": "Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "EPI-7386 (QD)",
          "type": "DRUG"
        },
        {
          "name": "EPI-7386 (BID)",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone acetate",
          "type": "DRUG"
        },
        {
          "name": "Apalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ESSA Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 71,
      "start_date": "2020-06-23",
      "completion_date": "2024-12-03",
      "has_results": false,
      "last_update_posted_date": "2025-02-28",
      "last_synced_at": "2026-09-22T20:56:59.834Z",
      "location_count": 7,
      "location_summary": "Port Saint Lucie, Florida • Atlanta, Georgia • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Port Saint Lucie",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04421222"
    },
    {
      "nct_id": "NCT03808610",
      "title": "Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Recurrent B Acute Lymphoblastic Leukemia",
        "Recurrent T Acute Lymphoblastic Leukemia",
        "Refractory B Acute Lymphoblastic Leukemia",
        "Refractory T Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Nelarabine",
          "type": "DRUG"
        },
        {
          "name": "Pegaspargase",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 53,
      "start_date": "2019-04-03",
      "completion_date": "2026-05-05",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-09-22T20:56:59.834Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03808610"
    }
  ]
}